NCT04943653View on ClinicalTrials.gov

Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Stomach NeoplasmsPaclitaxelPeritoneal Metastases
Interventions
DRUG

Paclitaxel

"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"

Trial Locations (1)

06591

RECRUITING

Gastric cancer center, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Seoul St. Mary's Hospital

OTHER